Deutsche Bank AG Takes Position in Pharvaris N.V. $PHVS

Deutsche Bank AG acquired a new position in shares of Pharvaris N.V. (NASDAQ:PHVS) during the 2nd quarter, Holdings Channel reports. The fund acquired 53,469 shares of the company’s stock, valued at approximately $1,849,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in PHVS. JPMorgan Chase & Co. boosted its stake in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the period. Barclays PLC acquired a new position in Pharvaris during the 4th quarter valued at about $77,000. CoreCap Advisors LLC purchased a new position in Pharvaris in the 2nd quarter worth $93,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Pharvaris during the 4th quarter valued at about $110,000. Finally, Nano Cap New Millennium Growth Fund L P purchased a new stake in Pharvaris in the fourth quarter valued at approximately $139,000.

Pharvaris Stock Performance

Shares of PHVS stock opened at $35.32 on Friday. The firm has a market cap of $2.31 billion, a P/E ratio of -11.58 and a beta of -2.31. The firm’s 50 day moving average price is $34.61 and its 200-day moving average price is $30.75. Pharvaris N.V. has a one year low of $20.65 and a one year high of $38.13.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). As a group, research analysts predict that Pharvaris N.V. will post -3.15 EPS for the current fiscal year.

Analysts Set New Price Targets

PHVS has been the subject of a number of recent research reports. Morgan Stanley lifted their price objective on Pharvaris from $41.00 to $46.00 and gave the company an “overweight” rating in a research note on Thursday, June 25th. Wall Street Zen downgraded shares of Pharvaris from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Guggenheim lifted their price target on Pharvaris from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research report on Friday, July 17th. Finally, New Street Research set a $60.00 target price on Pharvaris in a report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $51.08.

Insider Transactions at Pharvaris

In other news, CEO Berndt Modig sold 2,292 shares of Pharvaris stock in a transaction on Friday, August 14th. The stock was sold at an average price of $34.77, for a total value of $79,692.84. Following the completion of the sale, the chief executive officer directly owned 130,625 shares of the company’s stock, valued at approximately $4,541,831.25. The trade was a 1.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total value of $1,089,968.88. Following the completion of the sale, the director owned 315,167 shares in the company, valued at $11,185,276.83. This represents a 8.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 121,325 shares of company stock valued at $4,270,425. Corporate insiders own 11.84% of the company’s stock.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.